Meet our partners
Global Partner
Roche
Roche has been renowned for pharmaceutical medicines since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Read more at roche.com
News

Mar 2016 FDA grants Roche’s Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer

Feb 2016 U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis

Jan 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer


OneStart Europe Vision Film 2016

  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Matthew Foy, Partner, SR One
  • Sarah Haywood, CEO, MedCity 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Lynne Murray, Partnering and Strategy, MedImmune
  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Stephen Reese, Partner, Olswang LLP 
  • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 


From the OneStart London Bootcamp 2016

Seminar

Seminar: Business Model Innovation
  • Sonal Patel, External Innovation Group, Roche 
  • Richard Mason, PhD, Head of Johnson & Johnson Innovation, London, Johnson & Johnson Innovation 
  • Craig Rhodes, Business Innovation Manager in Health and Life Sciences, Intel Corporation 


Panel Discussion

Panel Discussion: Navigating Critical Decision Points
  • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune (Chair)
  • Matthias Essenpreis, PhD, Chief Technology Officer (Diagnostics), F.Hoffmann-La Roche Ltd.
  • Georg Buchner, PhD MBA, Licensing Director, Amgen 
  • Sarah Holland, DPhil (Oxon), MBA, External Science and Partnering, Sanofi
  • Jonathan Tobin, PhD, MBA, Principal, Healthcare Venture, Imperial Innovations


From the OneStart San Francisco Bootcamp 2016

Panel Discussion

Panel Discussion: Investors

  • Matthew Foy, Partner, SR One (Chair)
  • Tracy Saxton, PhD, Investment Director, Roche Venture Fund
  • Cayce Denton, VP, TPG Biotech 
  • Jenny Rooke, PhD, Manging Director, 5 Prime Ventures
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures


From the OneStart London Bootcamp 2015

Panel Discussion

Panel Discussion: Case Studies from Life Science Companies

  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC (Chair)
  • Sarah Holland, DPhil(Oxon), MBA, Life Cycle Leader alectinib, Roche
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
  • Chris Brown, MBA, Director, Scientific Licensing, Worldwide Business Development, GSK
  • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune

Mentors
Matthias Essenpreis
Chief Technology Officer, Roche Diagnostics + more
I am the Chief Technology Officer, Diagnostics at F. Hoffmann-La Roche Ltd. Prior to that, I was the Head Global Research and Technology of Roche Diabetes Care.
Simon Greenwood
Genentech Investment Director, Roche Venture Fund + more
I am an investment director for the Roche Venture Fund with more than 15 years of experience in the biotechnology industry. In this role, I have led investments in companies such as Allakos, Biodesy, CytomX, DVS (acquired by Fluidigm), Epic Sciences, Maculogix and Stratos. Prior to his role at the Roche Venture Fund, I was the head of GenenFund, Genentech’s corporate venture fund.
Teams Mentored